Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

@article{Leo2008PhaseID,
  title={Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.},
  author={Angelo di Leo and Henry Leonidas G{\'o}mez and Zeba Aziz and Zanete Zvirbule and Jos{\'e} Bines and Michael C. Arbushites and Stephanie F Guerrera and Maria Koehler and C. Priore Oliva and Steven H Stein and Lisa S Williams and Judy Dering and Richard S. Finn and Michael F Press},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 34},
  pages={
          5544-52
        }
}
PURPOSE Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2-positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of lapatinib in HER-2-negative and HER-2-uncharacterized MBC. PATIENTS AND METHODS Women with MBC were randomly assigned to first-line therapy with paclitaxel 175 mg/m(2) every 3 weeks plus lapatinib 1… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 185 extracted citations

The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

Annals of oncology : official journal of the European Society for Medical Oncology • 2011
View 10 Excerpts
Highly Influenced

Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?

Annals of oncology : official journal of the European Society for Medical Oncology • 2010
View 15 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…